Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 19/20 | 0.83 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Suvorexant SCHEMBL13731245 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL1586289 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL1820881 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL17539233 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL29357712 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| Suvorexant SCHEMBL29596480 | 0.91 | HCRTR2 (1.00) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL13372948 | 0.89 | HCRTR2 (0.85) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1653764 | 0.89 | HCRTR2 (0.84) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1818107 | 0.89 | HCRTR2 (0.84) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 | |
| SCHEMBL1651046 | 0.88 | HCRTR2 (0.82) | HCRTR2HCRTR1NR1I2ADRA2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195957-A1 | SUBSTITUTED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR2 1/4885HCRTR1 2/4885NR1I2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.